GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Akero Therapeutics Inc (NAS:AKRO) » Definitions » Float Percentage Of Total Shares Outstanding

Akero Therapeutics (Akero Therapeutics) Float Percentage Of Total Shares Outstanding : 97.58% (As of May. 01, 2024)


View and export this data going back to 2019. Start your Free Trial

What is Akero Therapeutics Float Percentage Of Total Shares Outstanding?

Float percentage of total shares outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Akero Therapeutics's float shares is 67.48 Mil. Akero Therapeutics's total shares outstanding is 69.15 Mil. Akero Therapeutics's float percentage of total shares outstanding is 97.58%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Akero Therapeutics's Insider Ownership is 1.92%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Akero Therapeutics's Institutional Ownership is 38.93%.

Akero Therapeutics Float Percentage Of Total Shares Outstanding Calculation

It is the percentage of float shares out of the total shares outstanding.

Akero Therapeutics's Float Percentage of Total Shares Outstanding for today is calculated as follows:

Float Percentage of Total Shares Outstanding=Float Shares/Total Shares Outstanding
=67.48/69.15
=97.58%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Akero Therapeutics (Akero Therapeutics) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Akero Therapeutics Inc (NAS:AKRO) » Definitions » Float Percentage Of Total Shares Outstanding
Comparable Companies
NVAX INBX RGNX ADPT KYMR RVNC AMAM PHVS KURA VERV OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
0K4:Germany 0K4:Germany
Address
601 Gateway Boulevard, Suite 350, South San Francisco, CA, USA, 94080
Website
https://www.akerotx.com
Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis, or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that has the potential to address the core processes underlying NASH pathogenesis.
Executives
Jonathan Young officer: Chief Operating Officer C/O AKERO THERAPEUTICS, INC., 170 HARBOR WAY 3RD FL, SOUTH SAN FRANCISCO CA 94080
Andrew Cheng director, officer: President & CEO 170 HARBOR WAY, 3RD FLOOR, C/O AKERO THERAPEUTICS, INC., SOUTH SAN FRANCISCO CA 94080
Catriona Yale officer: Chief Development Officer C/O AKERO THERAPEUTICS INC., 170 HARBOR WAY 3RD FLOOR, SOUTH SAN FRANCISCO CA 94080
William Richard White officer: Chief Financial Officer C/O AKERO THERAPEUTICS, INC., 170 HARBOR WAY 2ND FLOOR, SOUTH SAN FRANCISCO CA 94080
Timothy Rolph officer: Chief Scientific Officer C/O AKERO THERAPEUTICS, INC., 170 HARBOR WAY, 3RD FLOOR, SOUTH SAN FRANCISCO CA 94080
G. Walmsley Graham director ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104
Tomas J. Heyman director C/O AKERO THERAPEUTICS, INC., 170 HARBOR WAY 3RD FLOOR, SOUTH SAN FRANCISCO CA 94080
Jane Henderson director C/O ELEVEN BIOTHERAPEUTICS, INC., 215 FIRST STREET, CAMBRIDGE MA 02142
Patrick Lamy officer: See Remarks AKERO THERAPEUTICS, INC., 601 GATEWAY BOULEVARD, SUITE 350, SOUTH SAN FRANCISCO CA 94080
Skorpios Trust other: Former 10% owner 195 ARCH. MAKARIOS III AVE., NEOCLEOUS HOUSE, LIMASSOL G4 3030
Montrago Trustees Ltd other: Former 10% owner 195 ARCH. MAKARIOS III AVE., NEOCLEOUS HOUSE, LIMASSOL G4 3030
Blue Horizon Enterprise Ltd other: Former 10% owner 3076, SIR FRANCIS DRAKES HIGHWAY, ROAD TOWN, TORTOLA D8 VG1110
Ezbon International Ltd other: Former 10% owner 3076, SIR FRANCIS DRAKES HIGHWAY, ROAD TOWN, TORTOLA D8 VG1110
Seth Loring Harrison director 230 PARK AVENUE, SUITE 2800, NEW YORK NY 10169
Chou Judy director C/O AKERO THERAPEUTICS, INC., 601 GATEWAY BLVD, SUITE 350, SOUTH SAN FRANCISCO CA 64080